{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T01:26:28Z","timestamp":1771464388080,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013712","name":"Department of Human Services, Government of South Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013712","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003747","name":"Department of Health, State Government of Victoria","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003747","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006065","name":"Department of Health, Government of Western Australia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001786","name":"University of Adelaide","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001786","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.vaccine.2020.11.056","type":"journal-article","created":{"date-parts":[[2020,12,2]],"date-time":"2020-12-02T08:35:50Z","timestamp":1606898150000},"page":"332-342","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy of m-Health for the detection of adverse events following immunization \u2013 The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial"],"prefix":"10.1016","volume":"39","author":[{"given":"M.S.","family":"Gold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Lincoln","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Cashman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Braunack-Mayer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Stocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.11.056_b0005","unstructured":"Shameer A. World Health Organisation Global vaccine Safety Blueprint. https:\/\/www.who.int\/docs\/default-source\/documents\/global-vaccine-safety-blueprint-1-2012.pdf (accessed 6\/5\/20)"},{"issue":"1","key":"10.1016\/j.vaccine.2020.11.056_b0010","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13012-016-0510-7","article-title":"Factors That Influence the Implementation of E-Health: A Systematic Review of Systematic Reviews (An Update)","volume":"11","author":"Stevenson","year":"2016","journal-title":"Implement Sci"},{"key":"10.1016\/j.vaccine.2020.11.056_b0015","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fpubh.2016.00036","article-title":"Can Digital Tools Be Used for Improving Immunization Programs?","volume":"4","author":"Tozzi","year":"2016","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2020.11.056_b0020","doi-asserted-by":"crossref","unstructured":"Heininger U, Holm K, Caplanusi I et al Guide to active vaccine safety surveillance: Report of CIOMS working group on vaccine safety \u2013 executive summary Vaccine 20187 35:3917-3921","DOI":"10.1016\/j.vaccine.2017.06.033"},{"issue":"8","key":"10.1016\/j.vaccine.2020.11.056_b0025","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/00005650-199908000-00010","article-title":"Influence of physicians\u2019 attitudes on reporting adverse drug events: a case-control study","volume":"37","author":"Figueiras","year":"1999","journal-title":"Med Care"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.056_b0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1590\/S0080-623420140000400023","article-title":"Causes for the underreporting of adverse drug events by health professionals: a systematic review","volume":"48","author":"Guimaraes","year":"2014","journal-title":"Rev Esc Enferm USP"},{"issue":"362\u20137.","key":"10.1016\/j.vaccine.2020.11.056_b0035","article-title":"Feasibility of telemonitoring for active surveillance of influenza vaccine safety in the primary care setting in The Netherlands","volume":"15","author":"Vrijhoef","year":"2009","journal-title":"J Telemed Telecare"},{"issue":"4","key":"10.1016\/j.vaccine.2020.11.056_b0040","doi-asserted-by":"crossref","first-page":"297","DOI":"10.7883\/yoken.64.297","article-title":"Active surveillance of adverse events following immunization against pandemic influenza A (H1N1) in Korea","volume":"64","author":"Choe","year":"2011","journal-title":"Jpn J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2020.11.056_b0045","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.vaccine.2011.12.041","article-title":"Active surveillance for influenza vaccine adverse events: the integrated vaccine surveillance system","volume":"30","author":"Newes-Adeyi","year":"2012","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.056_b0050","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/j.1365-2125.2011.04142.x","article-title":"Influenza H1N1 (swine flu) vaccination: a safety surveillance feasibility study using self-reporting of serious adverse events and pregnancy outcomes","volume":"73","author":"Mackenzie","year":"2012","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.vaccine.2020.11.056_b0055","article-title":"Use of a text message-based pharmacovigilance tool in Cambodia: pilot study","author":"Baron","year":"201315468","journal-title":"J Med Internet Res."},{"key":"10.1016\/j.vaccine.2020.11.056_b0060","doi-asserted-by":"crossref","unstructured":"Tsafack M, Ateudjieu J. Improving community based AEFI (Adverse Events Following Immunization) reporting rate through telephone \u201cbeep\u201d in a Cameroon health district: a randomized field trial. Pan Afr Med J. 2015;22:351. Published 2015 Dec 11. doi:10.11604\/pamj.2015.22.351.8368.","DOI":"10.11604\/pamj.2015.22.351.8368"},{"issue":"7","key":"10.1016\/j.vaccine.2020.11.056_b0065","first-page":"1738","article-title":"An evaluation of the feasibility and usability of a proof of concept mobile app for adverse event reporting post influenza vaccination","volume":"12","author":"Wilson","year":"2016","journal-title":"Hum Vaccin Immunother"},{"issue":"1","key":"10.1016\/j.vaccine.2020.11.056_b0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2010-000016","article-title":"Epidemiological study of severe febrile reactions in young children in Western Australia caused by a 2010 trivalent inactivated influenza vaccine","volume":"1","author":"Armstrong","year":"2011","journal-title":"BMJ Open"},{"issue":"32","key":"10.1016\/j.vaccine.2020.11.056_b0075","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1016\/j.vaccine.2011.05.054","article-title":"Trivalent influenza vaccine and febrile adverse events in Australia, 2010: clinical features and potential mechanisms","volume":"29","author":"Blyth","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.056_b0080","unstructured":"AusVaxSafety http:\/\/ausvaxsafety.org.au\/ (accessed 6\/05\/20)."},{"key":"10.1016\/j.vaccine.2020.11.056_b0085","unstructured":"Definitions and application of terms of vaccine pharmacovigilance 2012: (accessed 21\/5\/201). https:\/\/cioms.ch\/publications\/product\/definitions-and-applications-of-terms-for-vaccine-pharmacovigilance\/."},{"key":"10.1016\/j.vaccine.2020.11.056_b0090","doi-asserted-by":"crossref","unstructured":"Fleiss, J. L., B. Levin, and M. C. Paik. Statistical Methods for Rates and Proportions 2003. 3rd ed. New York: Wiley.","DOI":"10.1002\/0471445428"},{"key":"10.1016\/j.vaccine.2020.11.056_b0095","doi-asserted-by":"crossref","unstructured":"Parrella A, Braunack-Mayer A, Gold M, Marshall H, Baghurst P. Healthcare providers' knowledge, experience and challenges of reporting adverse events following immunisation: a qualitative study. BMC Health Serv Res. 2013;13:313. Published 2013 Aug 15. doi:10.1186\/1472-6963-13-313","DOI":"10.1186\/1472-6963-13-313"},{"issue":"5","key":"10.1016\/j.vaccine.2020.11.056_b0100","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/j.vaccine.2019.11.050","article-title":"Barriers to healthcare workers reporting adverse events following immunization in four regions of Ghana","volume":"38","author":"Gidudu","year":"2020","journal-title":"Vaccine"},{"issue":"12","key":"10.1016\/j.vaccine.2020.11.056_b0105","doi-asserted-by":"crossref","first-page":"3726","DOI":"10.4161\/hv.34369","article-title":"Consumer reporting of adverse events following immunization [published correction appears","volume":"10","author":"Clothier","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.11.056_b0110","doi-asserted-by":"crossref","unstructured":"Dey A, Wang H, Quinn H, et al. Surveillance of adverse events following immunisation in Australia annual report, 2017. Commun Dis Intell (2018). 2019;43:10.33321\/cdi.2019.43.29. Published 2019 Jul 16. doi:10.33321\/cdi.2019.43.29","DOI":"10.33321\/cdi.2019.43.29"},{"issue":"42","key":"10.1016\/j.vaccine.2020.11.056_b0115","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1016\/j.vaccine.2014.07.061","article-title":"Vaxtracker: Active on-line surveillance for adverse events following inactivated influenza vaccine in children","volume":"32","author":"Cashman","year":"2014","journal-title":"Vaccine"},{"issue":"31","key":"10.1016\/j.vaccine.2020.11.056_b0120","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1016\/j.vaccine.2015.06.022","article-title":"Comparison of text-messaging to voice telephone interviews for active surveillance of adverse events following immunisation","volume":"33","author":"Regan","year":"2015","journal-title":"Vaccine"},{"issue":"18","key":"10.1016\/j.vaccine.2020.11.056_b0125","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1016\/j.vaccine.2019.02.082","article-title":"Participant centred safety surveillance of health care workers receiving influenza vaccination","volume":"37","author":"Cashman","year":"2019","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.056_b0130","unstructured":"AVS reports (Influenza Report No. 5 \u2022 15 May 2020), Men ACWY (Report No. 23 \u2022 15 May 2020) HPV (Report No. 55 \u2022 15 May 2020) (accessed 15 August 2020). http:\/\/www.ausvaxsafety.org.au\/safety-data."},{"key":"10.1016\/j.vaccine.2020.11.056_b0135","doi-asserted-by":"crossref","unstructured":"Munnoch SA, Cashman P, Peel R, Attia J, Hure A, Durrheim DN. Participant-Centered Online Active Surveillance for Adverse Events Following Vaccination in a Large Clinical Trial: Feasibility and Usability Study. J Med Internet Res. 2019;21(10):e14791. Published 2019 Oct 23. doi:10.2196\/14791","DOI":"10.2196\/14791"},{"issue":"2","key":"10.1016\/j.vaccine.2020.11.056_b0140","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1080\/14760584.2017.1264272","article-title":"Rapid assessment of the reactogenicity of a 2016\u20132017 seasonal influenza vaccine: results from a feasibility study","volume":"16","author":"Stuurman","year":"2017","journal-title":"Expert Rev Vaccines."},{"issue":"3","key":"10.1016\/j.vaccine.2020.11.056_b0145","doi-asserted-by":"crossref","first-page":"e204079","DOI":"10.1001\/jamanetworkopen.2020.4079","article-title":"Comparative Postmarket Safety Profile of Adjuvanted and High-Dose Influenza Vaccines in Individuals 65 Years or Older","volume":"5","author":"Pillsbury","year":"2020","journal-title":"JAMA Netw Open."},{"issue":"51","key":"10.1016\/j.vaccine.2020.11.056_b0150","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1016\/j.vaccine.2017.10.091","article-title":"AusVaxSafety consortium. Active SMS-based influenza vaccine safety surveillance in Australian children","volume":"35","author":"Pillsbury","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.11.056_b0155","doi-asserted-by":"crossref","unstructured":"Pillsbury AJ, Glover C, Jacoby P, et al. Active surveillance of 2017 seasonal influenza vaccine safety: an observational cohort study of individuals aged 6 months and older in Australia. BMJ Open. 2018;8(10):e023263. Published 2018 Oct 18. doi:10.1136\/bmjopen-2018-023263","DOI":"10.1136\/bmjopen-2018-023263"},{"key":"10.1016\/j.vaccine.2020.11.056_b0160","doi-asserted-by":"crossref","unstructured":"Pillsbury A, Cashman P, Leeb A, et al. Real-time safety surveillance of seasonal influenza vaccines in children, Australia, 2015. Euro Surveill. 2015;20(43):10.2807\/1560-7917.ES.2015.20.43.30050. doi:10.2807\/1560-7917.ES.2015.20.43.30050","DOI":"10.2807\/1560-7917.ES.2015.20.43.30050"},{"issue":"31","key":"10.1016\/j.vaccine.2020.11.056_b0165","doi-asserted-by":"crossref","first-page":"5000","DOI":"10.1016\/j.vaccine.2011.04.099","article-title":"Real-life versus package insert: a post-marketing study on adverse-event rates of the virosomal hepatitis A vaccine Epaxal\u00ae in healthy travellers","volume":"29","author":"Hatz","year":"2011","journal-title":"Vaccine."},{"key":"10.1016\/j.vaccine.2020.11.056_b0170","unstructured":"Review of the management of adverse events associated with Panvax and Fluvax Review by Professor John Horvath 2011. (accessed 21\/5\/2020). https:\/\/www.health.gov.au\/resources\/publications\/review-of-the-management-of-adverse-events-associated-with-panvax-and-fluvax."},{"issue":"2","key":"10.1016\/j.vaccine.2020.11.056_b0175","doi-asserted-by":"crossref","first-page":"e031851","DOI":"10.1136\/bmjopen-2019-031851","article-title":"Timeliness of signal detection for adverse events following influenza vaccination in young children: a simulation case study","volume":"10","author":"Jacoby","year":"2020","journal-title":"BMJ Open."},{"key":"10.1016\/j.vaccine.2020.11.056_b0180","doi-asserted-by":"crossref","unstructured":"Clothier HJ, Lawrie J, Russell MA, Kelly H, Buttery JP. Early signal detection of adverse events following influenza vaccination using proportional reporting ratio, Victoria, Australia. PLoS One. 2019;14(11):e0224702. Published 2019 Nov 1. doi:10.1371\/journal.pone.0224702","DOI":"10.1371\/journal.pone.0224702"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20315097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:54:01Z","timestamp":1759402441000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20315097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S0264410X20315097"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.056","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of m-Health for the detection of adverse events following immunization \u2013 The stimulated telephone assisted rapid safety surveillance (STARSS) randomised control trial","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.056","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Crown Copyright \u00a9 2020 Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}